

In the Claims:

a2  
Claim 3. (Amended) An implant as claimed in claim 1 [or claim 2,] wherein the parasitocidal compound has an aqueous solubility below 100 µg/ml.

Claim 4. (Amended) An implant as claimed in [claim 3,] claim 1, wherein the parasitocidal compound is an avermectin or a milbemycin.

Claim 5. (Amended) An implant as claimed in [claim 4,] claim 1, wherein the parasitocidal compound is doramectin.

Dr B2  
Claim 6. (Amended) An implant as claimed in [any one of the preceding claims,] claim 1 wherein the bulking agent is lactose.

Claim 7. (Amended) An implant as claimed in [any one of the preceding claims,] claim 1 wherein the tableting excipients include magnesium stearate.

Claim 8. (Amended) An implant as claimed in [any one of the preceding claims,] claim 1 wherein the tableting excipients include a tablet disintegrant.

Sub B3  
Claim 9. (Amended) An implant as claimed in claim 8, wherein the tablet disintegrant is sodium starch glycolate.

Claim 10. (Amended) An implant as claimed [any one of the preceding claims,] claim 1 which contains an antioxidant or a reducing agent.

Claim 11. (Amended) An implant as claimed in [claim 10,] claim 1, wherein the antioxidant is butylated hydroxy toluene or butylated hydroxy anisole.

Sub B4  
Claim 12. (Amended) An implant as claimed in [any one of the preceding claims,] claim 1 which is suitable for sterilization, or has been sterilized, by irradiation.

Claim 13. (Amended) An implant as claimed in [any one of the preceding claims,] claim 1 wherein the tableting excipients include polyvinyl pyrrolidone.

- Sub a3

[illegible]

02/NS